Scott M. Rocklage had become a Venture Partner with 5AM Ventures in 2003. Later, he became a Managing Partner in 2004.
Scott M. Rocklage comes with over 30 years of management experience in healthcare. He has handled strategic leadership responsibilities. All this has led to FDA approval for three U.S. New Drug Applications. These are namely Omniscan™, Teslascan® along with Cubicin®.
Scott M. Rocklage has served as the Chairman as well as CEO of Cubist Pharmaceuticals. He has been the President and CEO of Nycomed Salutar. He has also been in R&D positions at Salutar and Catalytica. He was formerly the Board Chairman of Relypsa and Novira, that has now been acquired by J&J.
Currently Scott M. Rocklage serves as Board Chairman of Rennovia, Kinestral and Cidara. He is also an inventor or co-inventor of more than 30 U.S. patents. He is credited with over 100 peer-reviewed publications. He is based in the Boston, MA office.
Scott M. Rocklage believes that MIT is responsible for setting the foundation for his professional career. He expressed immense gratitude toward its Chemistry Department. Hence he and his wife visited the department on July 18, 2016. He gifted them assistance with the costs that would be associated with renovating the Lester Wolfe Professor of Chemistry, and Moungi Bawendi’s nanochemistry as well as nanotechnology lab space that is in Building 2.
Basically Scott M. Rocklage had completed his PhD studies in the Department of Chemistry here. This was under the tutelage of Nobel Prize winner in Chemistry, Professor Richard R. Schrock.
On this day, Scott M. Rocklage toured the newly renovated lab space that has been given by Professor Bawendi along with two of his graduate students, Whitney Hess and He Wei. Then all the Bawendi group members as well as faculty gathered in the vestibule of the lab that has a display of a plaque honoring the Rocklages.